The miR-200 family controls -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients
Susanna Leskelä(Spanish National Cancer Research Centre), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Inés G. Muñoz(Spanish National Cancer Research Centre), Beatriz Martínez–Delgado(Centre for Biomedical Network Research on Rare Diseases), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Jorge Barriuso(Queen's University Belfast), David Hardisson(Universidad Autónoma de Madrid), Lucía Inglada‐Pérez(Spanish National Cancer Research Centre), Andrés Redondo(Hospital Universitario La Paz), Marta Mendiola(Hospital Universitario La Paz), J. de Santiago(Hospital Universitario La Paz), Luis J. Leandro‐García(Spanish National Cancer Research Centre)
Cited by 207
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
|Nature Genetics|2011|528
Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension
|Journal of Hypertension|2020|406
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
|Human Molecular Genetics|2013|394
<i>MAX</i> Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma
|Clinical Cancer Research|2012|330